Role of silibinin in the management of diabetes mellitus and its complications
Diabetes mellitus is globally approaching epidemic proportions and acts as a major cause of a number of serious health problems diagnosed as diabetic complications. The current oral drugs in the treatment of diabetes and its complications could meet some but not all of the patients’ needs, and the development of novel drugs with a hypoglycemic effect is urgently required. Silibinin, a flavonolignan traditionally used for the treatment of gallbladder and hepatic diseases, was reported to improve glycemic homeostasis by improving the activity of pancreatic β-cells, increasing insulin sensitivity of liver and muscle cells, and decreasing lipid deposition in adipocytes. Researches also indicated the effectiveness of silibinin in controlling several diabetic complications including neuropathy, retinopathy, impaired healing, hepatopathy, cardiomyopathy, nephropathy, and osteoporosis. In this review, we summarize the recent anti-diabetes findings of silibinin and clarify the underlying pharmacological mechanisms, and update the knowledge in understanding the role of silibinin in control of diabetic complications.
KeywordsDiabetes mellitus Diabetic complications Silibinin Hypoglycemic potential Pharmacological mechanisms
This work was supported by China Postdoctoral Science Foundation (2017M621161; 2018T110462), Doctoral Starting up Foundation of Liaoning Science and Technology Department (201601139), Foundation of Liaoning Education Committee (201610163L26), National Natural Science Foundation of China (81573580; 81503229), Key Laboratory of Polysaccharide Bioactivity Evaluation of TCM of Liaoning Province and Key Laboratory of Quality Control of TCM of Liaoning Province (17-137-1-00).
Compliance with ethical standards
Conflict of interest
The authors have declared no conflict of interest.
- Chang CL, Lin Y, Bartolome AP, Chen YC, Chiu SC, Yang WC (2013) Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. Evid-Based Compl Alt 2013:378657Google Scholar
- Chen K, Xu J, He H, Zhao L, Xiong J, Mo Z (2015) Protective effect of silibinin on islet beta cells in C57BL/6 J mice fed a highfat diet. J Cent South Univ Med Sci 40:165–170Google Scholar
- Ebrahimpour Koujan S, Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M (2015) Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine 22(2):290–296CrossRefPubMedGoogle Scholar
- Federico A, Andreone P, Brisc MC, Chiaramonte M, Floreani A, Freni MA, Grieco A, Lobello S, Milani S, Okolicsanyi L, Portincasa P, Smedile A, Sporea I, Vecchione R, Blanco CDV, Okolicsanyi L (2010) Effect of silybin in patients with chronic hepatitis: preliminary results of a multicentre randomized controlled trial vs placebo. Gastroenterology 138(5):800CrossRefGoogle Scholar
- Fu J, Cui Q, Yang B, Hou Y, Wang H, Xu Y, Wang D, Zhang Q, Pi J (2017) The impairment of glucose-stimulated insulin secretion in pancreatic beta-cells caused by prolonged glucotoxicity and lipotoxicity is associated with elevated adaptive antioxidant response. Food Chem Toxicol 100:161–167CrossRefPubMedGoogle Scholar
- International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. IDF, BrusselsGoogle Scholar
- Ishii E, Bracht A (1986) Glucose release by the liver under conditions of reduced activity of glucose 6-phosphatase. Braz J Med Biol Res 20:837–843Google Scholar
- Jain D, Somani R, Gilhotra R (2016) Silibinin ameliorates hyperglycaemia, hyperlipidemia and prevent oxidative stress in streptozotocin induced diabetes in Sprague Dawley rats. Int J Pharm Res Allied Sci 5(3):136–144Google Scholar
- Khalili N, Fereydoonzadeh R, Mohtashami R, Mehrzadi S, Heydari M, Huseini HF (2017) Silymarin, olibanum, and nettle, a mixed herbal formulation in the treatment of type II diabetes: a randomized, double-blind, Placebo-controlled, clinical trial. J Evid Based Complement Altern Med 22(4):603–608CrossRefGoogle Scholar
- Rahimi R, Karimi J, Khodadadi I, Tayebinia H, Kheiripour N, Hashemnia M, Goli F (2018) Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes. Biomed Pharmacother 101:244–250CrossRefPubMedGoogle Scholar
- Somesh BP, Verma MK, Sadasivuni MK, Mammenoommen A, Biswas S, Shilpa PC, Reddy AK, Yateesh AN, Pallavi PM, Nethra S, Smitha R, Neelima K, Narayanan U (2013) Jagannath MR (2013) Chronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activity. BMC Cell Biol 14:31CrossRefPubMedPubMedCentralGoogle Scholar
- Wang Q, Liu M, Liu WW, Hao WB, Tashiro S, Onodera S, Ikejima T (2012) In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic beta-cell. J Asian Nat Prod Res 14:413–423CrossRefPubMedGoogle Scholar